Insmed To Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced its participation in a fireside chat at the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 12:00 p.m. ET. The event aims to highlight Insmed's commitment to transforming lives through its innovative approaches to serious and rare diseases. The chat will be accessible via the investor relations section on the company's website and will be archived for 30 days post-event. Insmed's first product treats a debilitating lung disease, with ongoing development of therapies targeting unmet medical needs.

BRIDGEWATER, N.J., Feb. 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 12:00 p.m. ET.

The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations 
Insmed
(718) 594-5332
eleanor.barisser@insmed.com 

Media:

Mandy Fahey 
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-svb-securities-global-biopharma-conference-301740029.html

SOURCE Insmed Incorporated

FAQ

When will Insmed present at the SVB Securities Global Biopharma Conference?

Insmed will present on February 14, 2023, at 12:00 p.m. ET.

How can I access the Insmed presentation from the conference?

The presentation will be webcast live and can be accessed on Insmed's investor relations website.

What is Insmed's focus in the biopharmaceutical industry?

Insmed focuses on developing therapies for serious and rare diseases.

What is the ticker symbol for Insmed?

The ticker symbol for Insmed is INSM.

What notable product has Insmed launched?

Insmed's first commercial product is a first-in-disease therapy for a chronic lung disease.